Table 1 Baseline demographics and clinical data
No. of patients | 62 |
Gender (M:F) | 16:46 |
Age at time of surgery (years) | 52.6 ± 12.2 |
Body weight (kg) | 52.9 (46–65) |
Underlying renal diagnosis, no. of patients (%) | |
Diabetic nephropathy | 9 (14.5) |
Hypertensive nephropathy | 10 (16.1) |
Polycystic kidney | 4 (6.5) |
Glomerulonephritis | 20 (32.2) |
Unknown | 19 (30.6) |
RRT at time of surgery | |
PD | 45 (72.6) |
HD | 17 (27.4) |
Duration of dialysis (years) | 5.9 ± 2.6 |
Kt/V (weekly) | 2.31 ± 0.9 |
Preoperative serum biochemistry | |
iPTH–peak (pmol/L) | 170 (131–221) |
iPTH–immediately before operation (pmol/L) | 156.5 (122–215) |
ALP–peak (IU/L) | 309.5 (192–511) |
ALP–immediately before operation (IU/L) | 261 (161–447) |
Calciuma (mmol/L) | 2.57 ± 0.21 |
Phosphate (mmol/L) | 2.28 ± 0.65 |
Albumin (g/L) | 31 ± 5 |
Haemoglobin (g/dL) | 9.9 ± 1.5 |
Preoperative drug treatment | |
Phosphate binders (n = 31) | |
Calcium carbonate (n = 21) (mg/day) | 2904.8 ± 1921.1 |
Aluminium hydroxide (n = 4) (mg/day) | 1400.0 ± 632.5 |
Lanthanum (n = 3) (mg/day) | 1083.3 ± 381.9 |
Sevelamer (n = 4) (mg/day) | 2100.0 ± 1194.4 |
Active vitamin D (n = 23) | |
Calcitriol (n = 3) (μg/week) | 1.00 ± 0.50 |
Alfacalcidol (n = 12) (μg/week) | 1.17 ± 0.83 |
Paricalcitol (n = 8) (μg/week) | 24.00 ± 14.30 |
Cinacalcet (n = 14) (mg/day) | 35.7 ± 16.2 |
Surgical procedure, no. of patients (%) | |
4 glands resected | 48 (77.4) |
Less than four glands resected | 14 (22.6) |
Weight of resected parathyroid tissue (g) | 2.56 ± 1.56 |
Pathology of parathyroid tissue, no. of patients (%) | |
Hyperplasia | 59 (95.2) |
Adenoma | 3 (4.8) |